Surrozen (SRZN) Receivables - Accured (2021 - 2022)

Surrozen (SRZN) posted quarterly Receivables - Accured of $167000.0 for Q3 2022, down 78.08% quarter-over-quarter from $762000.0 in Q4 2021.

Surrozen (SRZN) Receivables - Accured (2021 - 2022) Analysis & Trends

Surrozen's Receivables - Accured history runs 2 years deep, the most recent figure standing at $167000.0 for Q3 2022.

In Q3 2022, Receivables - Accured changed N/A year-over-year to $167000.0; the TTM figure through Sep 2022 stood at $167000.0 (changed N/A YoY), while the FY2021 annual figure was $762000.0, changed N/A from the prior year.
Receivables - Accured for Q3 2022 stood at $167000.0, down from $762000.0 in the prior quarter.
The five-year high for Receivables - Accured was $762000.0 in Q4 2021, with the low at $167000.0 in Q3 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Acc. Int. Receivables (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	-
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	-
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	-
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	-
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	-
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-
10	Surrozen	281.63 Mn	281.63 Mn	-	-

Download Data